Identification of a Novel Inhibitor of the NF-κB Pathway

ISSN: 1875-614X (Online)
ISSN: 1871-5230 (Print)

Volume 16, 3 Issues, 2017

Download PDF Flyer

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Inflammatory and Anti-Allergy Agents

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Submit Abstracts Online Submit Manuscripts Online

Claudiu T. Supuran
Neurofarba Department
University of Florence

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Identification of a Novel Inhibitor of the NF-κB Pathway

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, 1(1): 29-39.

Author(s): A. Misra-press, M. McMillan, E. Cudaback, M. Qabar, F. Ruan, M. Nguyen, T. Vaisar, H. Nakanishi and M Kahn.

Affiliation: Pacific Northwest Research Institute, 720 Broadway, Seattle, WA 98122, USA


NF-κB1 plays a central role in regulating genes involved in inflammatory responses, and its recently described role in oncogenesis reemphasizes its importance as a critical mediator of cellular function. We describe herein a novel inhibitor (MOL-294) of NF-κB driven transcription that does not inhibit the proteasome complex, does not inhibit IκB2 phosphorylation, and does not significantly inhibit nuclear translocation of the p65 / RelA subunit of NF-κB. We have identified thioredoxin, a cellular redox protein, which has previously been implicated in the regulation of NF-κB driven transcription, as one of the intracellular targets of MOL-294. The identification of a low molecular weight inhibitor of this type of redox protein represents a novel mechanism of inhibiting the NF-κB signaling pathway.


inhibitor, cytotoxicity.

Download Free Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 1
Issue Number: 1
First Page: 29
Last Page: 39
Page Count: 11
DOI: 10.2174/1568014024606566

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science